← Back to patent-cliff list
Clifutinib Besylate
Tier C — Watch / tradeClifutinib Besylate
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：FLT3
Indications (approved)：Acute myeloid leukaemia
Regional status
US
-
EU
-
China
Phase III
2023-03-03
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Clifutinib Besylate?
Approved indications include: Acute myeloid leukaemia.
When does the Clifutinib Besylate patent expire?
No public expiry year is available for Clifutinib Besylate yet; this page updates once verified.
How do I get a quote for Clifutinib Besylate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03